Pharmaceutical giant Eli Lilly faces a pivotal regulatory milestone in March 2026, with the U.S. Food and Drug Administration (FDA) poised to rule on Orforglipron. This oral GLP-1 weight-loss drug could secure approval as early as the second quarter. Concurrently, the company is advancing its clinical pipeline in China, targeting both Alzheimer’s disease and diabetes. This multi-front progress raises questions about the long-term sustainability of its current explosive growth trajectory.
Financial Performance and Product Concentration
Lilly’s recent financial results have been staggering. For 2025, total revenue surged to $65.2 billion, marking an increase of nearly 45% year-over-year, while profits nearly doubled. This performance was fueled by two blockbuster drugs: Mounjaro (for diabetes) and Zepbound (for weight loss), which saw sales leap by 99% and 175%, respectively.
However, this success reveals a significant concentration risk. These two products now account for 56% of the company’s total sales. This reliance underscores the strategic imperative for Lilly to successfully launch new therapies before key patents eventually expire.
The Oral GLP-1 Contender: Orforglipron
All eyes are on the FDA’s imminent decision regarding Orforglipron. Data from the 52-week ACHIEVE-3 study demonstrated its competitive edge. At a 36-milligram dose, the treatment reduced HbA1c levels by 2.2%, compared to 1.4% for oral semaglutid. It also prompted an average weight loss of 9.2%, versus 5.3% for the competitor.
Pricing for the new drug is already set. Starting in April, Medicare patients will pay a maximum of $50 monthly for either Zepbound or Orforglipron, while the lowest dose will be available to cash-paying patients for $149. Market research firm Clarivate forecasts that Orforglipron could generate $16 billion in annual revenue by 2031.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Strengthening the Global Footprint: Focus on China
Lilly is actively expanding its research presence in key international markets. Within the last 48 hours, the company initiated a Phase 1 trial in China for its Alzheimer’s candidate, Remternetug. This marks the first time the drug, which is already in global Phase 3 development, will be tested on Chinese subjects. A separate early-stage study for an oral diabetes medication is also underway in the region. The global market for Alzheimer’s treatments is projected to expand from $2.4 billion in 2023 to $17 billion by 2033, representing a compound annual growth rate of 21.8%.
Regulatory Progress in Europe
In Europe, the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Olumiant (baricitinib) for adolescents aged 12 to 18 with severe alopecia areata. In the supporting Phase 3 BRAVE-AA-PEDS trial, 42.4% of participants achieved at least 80% scalp coverage after 36 weeks. A final decision from the European Commission is anticipated within the next one to two months.
Navigating a Competitive Landscape
The competitive environment is intensifying. Rival Novo Nordisk is making a direct challenge to Lilly’s GLP-1 dominance with a $506 million investment in a new manufacturing facility in Ireland. Furthermore, Lilly’s equity currently trades at a price-to-earnings (P/E) ratio of 44, a valuation that investors weigh against the revenue concentration in just two products.
Looking ahead, Lilly has set an ambitious revenue target of approximately $83 billion for 2026. The coming weeks will be critical in determining whether Orforglipron’s potential approval can help underpin that forecast. Shareholders will also benefit from an increased quarterly dividend of $1.73 per share, payable on March 10, up from the previous $1.50 payout.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from March 5 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 5.
Eli Lilly: Buy or sell? Read more here...
